Cargando…

Insights on the use of biosimilars in the treatment of inflammatory bowel disease

Biologic therapy, such as those that target tumor necrosis factor (TNF) signaling, has proven to be an efficacious method of treatment for patients with inflammatory bowel disease (IBD) with regards to symptom management and mucosal healing. However, the rising prevalence of IBD worldwide and the ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Michael K, Shih, David Q, Chen, Gary C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360634/ https://www.ncbi.nlm.nih.gov/pubmed/28373759 http://dx.doi.org/10.3748/wjg.v23.i11.1932

Ejemplares similares

Current status of biosimilars in the treatment of inflammatory bowel diseases
por: Park, Dong Il
Publicado: (2016)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases
por: Solitano, Virginia, et al.
Publicado: (2021)

Biosimilars in paediatric inflammatory bowel disease
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2018)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
por: Al Sulais, Eman, et al.
Publicado: (2020)

Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
por: Park, Sang Hyoung, et al.
Publicado: (2020)

Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
por: Najeeb, Hala, et al.
Publicado: (2022)

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
por: Rawla, Prashanth, et al.
Publicado: (2018)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars
por: Hakizimana, Ali, et al.
Publicado: (2017)

Insights into the treatment of inflammatory bowel disease in pregnancy
por: Shannahan, Sarah E., et al.
Publicado: (2019)

Biosimilars in inflammatory bowel disease: A review of post-marketing experience
por: Deiana, Simona, et al.
Publicado: (2017)

Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients
por: Garcia, Karoline Soares, et al.
Publicado: (2021)

Response to Comments on the CAG/CCC Position Statement on Biosimilars for Inflammatory Bowel Disease
por: Moayyedi, Paul, et al.
Publicado: (2020)

Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies
por: Armuzzi, Alessandro, et al.
Publicado: (2019)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
por: Petric, Zvonimir, et al.
Publicado: (2022)

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease
por: Vernero, Marta, et al.
Publicado: (2023)

Switching from Infliximab to Biosimilar in Inflammatory Bowel Disease: A Review of Existing Literature and Best Practices
por: Bhat, Shubha, et al.
Publicado: (2021)

Joint Canadian Association of Gastroenterology and Crohn’s Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease
por: Moayyedi, Paul, et al.
Publicado: (2019)

Biosimilars in the management of chronic inflammatory diseases: The Dutch experience
por: Müskens, Wieland D., et al.
Publicado: (2019)

Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology
por: Mularczyk, Aldona, et al.
Publicado: (2014)

Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar
por: Meijboom, Rosanne W., et al.
Publicado: (2023)

Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2016)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment
por: Norouzinia, Mohsen, et al.
Publicado: (2017)

The microbiota in inflammatory bowel disease: current and therapeutic insights
por: Lane, Erin R, et al.
Publicado: (2017)

Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Financial Conflicts of Interest in Propensity Score-Matched Studies Evaluating Biologics and Biosimilars for Inflammatory Bowel Disease
por: Elsolh, Karam, et al.
Publicado: (2022)

Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease
por: Huoponen, Saara, et al.
Publicado: (2020)

Insights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease
por: Levy, Alexander N., et al.
Publicado: (2019)

Biosimilars and the extrapolation of indications for inflammatory conditions
por: Tesser, John RP, et al.
Publicado: (2017)

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
por: Strand, Vibeke, et al.
Publicado: (2019)

Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review
por: Bashir, Naazish S., et al.
Publicado: (2023)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?
por: Bernasko, Nana, et al.
Publicado: (2021)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Inflammatory Bowel Disease Associated Colorectal Neoplasia
por: Vu, Michelle, et al.
Publicado: (2012)

Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
por: Pękala, Anna, et al.
Publicado: (2021)

Insight into the Relationship between Oral Microbiota and the Inflammatory Bowel Disease
por: Han, Yimin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ecuo0alm36m24ifdpu3qht37fg